This Oral Pill Beat Ozempic on Weight Loss, But Almost 1 in 10 People Quit It

There's a new oral GLP-1 drug, and it didn't just perform "about as well" as oral semaglutide, the active ingredient in Rybelsus, Ozempic, and Wegovy.

It beat it.

The drug is called orforglipron, developed by Eli Lilly, and the results just published in The Lancet come from a proper head-to-head phase 3 trial, not a marketing claim.

The Actual Numbers

The trial followed 1,698 adults with type 2 diabetes across six countries for 52 weeks, comparing orforglipron directly against oral semaglutide.

On blood sugar control, orforglipron reduced HbA1c by 1.71–1.91%, compared to 1.47% for oral semaglutide.

On weight loss, participants taking orforglipron lost an average of 6.1–8.2 kg, compared to 5.3 kg for those on oral semaglutide.

In percentage terms, that's roughly 6–8% body weight lost on orforglipron, versus 4–5% on oral semaglutide.

Both drugs work, this one just worked harder.

Why It's Not a Simple Win

Here's the part that gets left out of the celebratory headlines.

Around 59% of participants on orforglipron reported gastrointestinal side effects like nausea, vomiting, diarrhea, or constipation, compared to 37–45% on semaglutide.

About 10% of people on orforglipron stopped treatment because of side effects, versus only 4–5% on semaglutide.

Researchers think this comes down to how orforglipron is absorbed, producing more pronounced daily peak drug concentrations than semaglutide does, which likely intensifies GI symptoms.

So the more effective drug is also, for a meaningful chunk of people, the harder one to actually stay on.

One More Detail Worth Knowing

Orforglipron doesn't require the empty-stomach timing that oral semaglutide does, and it doesn't need refrigeration.

That's a real practical advantage, since semaglutide tablets currently require being taken first thing in the morning with a small sip of water, then waiting 30 minutes before eating or drinking anything else.

It's also reportedly cheaper to manufacture, which matters for long-term access if it gets approved more broadly.

This trial was in people with type 2 diabetes. A related trial in people with obesity but without diabetes (ATTAIN-1) found even larger results: participants on the highest dose lost an average of 27.3 lbs, or about 12.4% of body weight, at 72 weeks.

Three Takeaways Worth Sitting With

1. "More effective" and "easier to stay on" are two different questions. Orforglipron wins on efficacy numbers, but the higher discontinuation rate means the real-world impact depends on whether people can tolerate it long enough to get those results.

2. Oral GLP-1 drugs are closing the gap with injectables faster than expected. A few years ago, injectable GLP-1s were clearly the more powerful option. The performance gap between oral and injectable is narrowing, which has real implications for accessibility and needle-aversion as a barrier to treatment.

3. Convenience factors matter as much as raw numbers for real adherence. No fasting requirement, no refrigeration, and a simpler dosing routine may end up mattering more for long-term outcomes than a few extra percentage points of weight loss on paper.

Three Practical Tips

Tip 1: If GI side effects are a concern, ask about dose titration. Slower dose increases are a standard strategy with GLP-1 drugs to reduce nausea and GI symptoms, and it's worth discussing with a prescriber rather than assuming discontinuation is the only option.

Tip 2: Don't treat trial averages as a personal guarantee. A 6–8% average weight loss includes a wide range of individual responses. Some people lose significantly more, some less, and GLP-1 response varies by individual biology.

Tip 3: Track how a new medication changes your routine, not just your weight. Since orforglipron doesn't require fasting or refrigeration, part of its real value is logistical simplicity. If ease of use makes you more consistent, that consistency itself is a legitimate part of treatment success.

Final Thoughts

The headline version of this story is simple: new pill beats old pill.

The more useful version is that effectiveness and tolerability are separate variables, and a drug that performs better on paper isn't automatically the better choice for every person taking it.

Orforglipron looks like a genuine step forward for oral GLP-1 treatment, but the higher side-effect and discontinuation rates are the trade-off that gets buried under the more shareable "beats Ozempic" framing.

If you were choosing between a slightly less effective drug you could tolerate long-term, and a more effective one you might not be able to stay on, which trade-off would actually work better for your life?